ALK-negative anaplastic large cell lymphoma

Summary

ALK-negative anaplastic large cell lymphoma (MONDO:0017603) is a cancer and 16 clinical trials. Top therapeutic interventions include cyclophosphamide anhydrous, doxorubicin, and brentuximab vedotin. A subtype of anaplastic large cell lymphoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Prevalence: Unknown (Worldwide)
• Clinical trials: 16

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	ALK-negative anaplastic large cell lymphoma
Mondo ID	MONDO:0017603
EFO	EFO:1000083
Orphanet	300903
ICD-10-CM	C84.7
NCIT	C37194
UMLS	C1332078
MedGen	272266
GARD	0021252
Is cancer (heuristic)	yes

Also known as: ALCL, ALK- · ALK- ALCL · ALK- anaplastic large cell lymphoma · ALK-negative anaplastic large cell lymphoma · anaplastic large cell lymphoma, ALK-negative

Data availability: 10 cell lines.

Disease family

This is a subtype of anaplastic large cell lymphoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hematopoietic and lymphoid system neoplasm › hematopoietic and lymphoid cell neoplasm › lymphoid neoplasm › T-cell and NK-cell neoplasm › neoplasm of mature T-cells or NK-cells › mature T-cell and NK-cell non-Hodgkin lymphoma › anaplastic large cell lymphoma › ALK-negative anaplastic large cell lymphoma

Related subtypes (4): central nervous system anaplastic large cell lymphoma, primary cutaneous anaplastic large cell lymphoma, ALK-positive anaplastic large cell lymphoma, small cell variant anaplastic large cell lymphoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 16.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1/PHASE2	5
PHASE2	5
PHASE1	2
Not specified	2
PHASE4	1
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01746992	PHASE4	UNKNOWN	CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma
NCT06724237	PHASE3	RECRUITING	Testing Whether High Dose Chemotherapy and Infusion of the Patients’ Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
NCT02223208	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas
NCT02978625	PHASE2	ACTIVE_NOT_RECRUITING	Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
NCT03113500	PHASE2	ACTIVE_NOT_RECRUITING	Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
NCT01035463	PHASE1/PHASE2	COMPLETED	Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma
NCT01198665	PHASE1/PHASE2	COMPLETED	RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas
NCT01719835	PHASE2	UNKNOWN	CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study
NCT02533700	PHASE2	UNKNOWN	CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL
NCT02561273	PHASE1/PHASE2	COMPLETED	Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin’s Lymphoma
NCT03493451	PHASE2	COMPLETED	Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
NCT04423926	PHASE1/PHASE2	UNKNOWN	Lenalidomide in Combination With CHOP in Patients With Untreated PTCL
NCT06176690	PHASE1	RECRUITING	Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
NCT04480788	PHASE1	UNKNOWN	CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study
NCT05978141	Not specified	RECRUITING	A Registry for People With T-cell Lymphoma
NCT03040206	Not specified	COMPLETED	Risk Stratification of Nodal PTCL

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CYCLOPHOSPHAMIDE ANHYDROUS	4	3
DOXORUBICIN	4	3
BRENTUXIMAB VEDOTIN	4	1
ETOPOSIDE	4	1
ETOPOSIDE PHOSPHATE	4	1
IFOSFAMIDE	4	1
METHOTREXATE	4	1
PREDNISONE	4	1
TALIMOGENE LAHERPAREPVEC	4	1
TISLELIZUMAB	4	1
VINCRISTINE	4	1
PIRARUBICIN	3	1
CHEMBL15720	0	1
CHEMBL426	0	1